
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Palmoplantar pustulosis (palmoplantar pustular psoriasis) presents a frustrating therapeutic challenge to clinicians and a disabling disease for patients deserving of greater research interest from the global dermatology community, says Robert J.G. Chalmers, M.B.B.S.